| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
This chapter of CNS Drug Discoveries focuses on the Alzheimer's disease and
Parkinson's disease sectors of the market for neurodegenerative drugs.
Approximately US$6.6 billion was spent in 2005 on the symptomatic treatment of
Alzheimer's disease (AD) and Parkinson's disease (PD). Although these
neurodegenerative diseases only affect around 1% of the population their
prevalence increases with age, thus these diseases are likely to become more
commonplace due to patient demographics and become a greater burden on health
care services.
Global Alzheimer's and Parkinson's market In 2005, approximately 45% of AD/PD
sales were derived from the US compared to 36% in Europe and the remainder
(19%) in international markets including Japan. The sale of AD and PD
medication varies between each country, for example 55% of AD drug sales are
derived from the US compared to 31% of PD drug sales. The treatment of AD
patients is dominated by the use of acetylcholinesterase inhibitors such as
Aricept (Eisai), Exelon (Novartis) and Razadyne (Johnson & Johnson) although
the use of the NMDA receptor antagonist Namenda/Ebixa (Forest/Lundbeck) is
gaining acceptance, particularly in the treatment of moderate to severe AD. In
contrast, PD patients are treated with a cocktail of drugs but predominantly
with dopaminergic drugs such as Levodopa and/or dopamine agonists either as a
monotherapy or in combination with catechol O-methyltransferase (COMT)
inhibitors or monoamine oxidase (MAO) inhibitors.
Over the next six years, we forecast the market will undergo a new wave of
treatments as the first disease-modifying agents (those that address the
underlying cause of the diseases rather than the symptoms) are launched. These
include Alzhemed (Neurochem), Flurizan (Myriad Genetics) and phenserine
(Axonyx) for the treatment of AD and spheramine (Schering AG) for the
treatment of PD.
TABLE OF CONTENTS
NEURODEGENERATION
- EXECUTIVE SUMMARY
- THE FACTS
- What is neurodegeneration and why are we interested in it?
- PATIENT STATISTICS
- Incidence, diagnosis rates and treatment; now and in the future
- PATIENT MODEL
- The addressable AD and PD patient population will grow by 2% per annum
- Summary of AD patient population forecasts 2005A-2012E
- Summary of PD patient population forecasts 2005A-2012E
- DRUG GROWTH DRIVERS
- DRUG GROWTH RISKS/DAMPENERS
GLOBAL AD/PD MARKET
- Global CNS Market (US$68.7 billion)
- GLOBAL SALES SPLIT
- AD and PD Global sales split (2005A)
- AD Global sales split (2005A)
- PD Global sales split (2005A)
- US market
- AD US drugs sales split (2005A)
- PD US drugs sales split (2005A)
- European market
- AD European drugs sales split (2005A)
- PD European drugs sales split (2005A)
- Japan
- Split between AD and PD in Japan (2005A)
- The major players
- Market Share of AD players by sales (Dec 2005A)
- Market Share of PD players by sales (Dec 2005A)
- Players and Products in 2012
- Market Share of AD players by sales (Dec 2012E)
- Players and Products in 2012
- Market Share of PD players by sales (Dec 2012E)
- CURRENT AD TREATMENTS
- CURRENT PD TREATMENTS
- Leading Brands
- Comparison of leading AD drugs
- Comparison of leading PD drug classes
- Patent Exposure of Current Products
- Patent Exposure of Leading AD Brands
- Patent Exposure of Leading PD Brands
- ANALYSIS OF LEADING BRANDS
- Acetylcholine Esterase (AChE) Inhibitors
- Aricept (Eisai)
- Exelon (Novartis)
- Razadyne (Johnson & Johnson/Shire)
- NMDA Antagonist
- Namenda/Ebixa (Forest/Lundbeck)
- Dopamine Agonists
- Apokyn (Britannia/Vernalis)
- Neupro (Schwarz Pharma)
- Sifrol/Mirapex/Mirapexin (Boehringer Ingelheim)
- Requip (GlaxoSmithKline)
- Monoaminoxidase (MAO) Inhibitors
- Catechol-O-Methyltransferase (COMT) Inhibitors
- Comtan/Comtess & Stalevo (Novartis)
- GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005 - 2012
- Sales Forecasts of Current Leading AD Drugs
- Sales Forecasts of Current Leading PD Drugs 2005 - 2012
- Model assumptions
- NEW DRUGS IN R&D
- Drugs in Development to Treat AD and PD
- ANALYSIS OF PHASE III DRUGS
- New Drugs in Phase III Development to Treat AD and PD
- AD Agents
- PD Agents
- AD Agents
- Alzhemed (Neurochem)
- Flurizan (Myriad Genetics)
- Phenserine (Axonyx)
- Xaliproden (sanofi-aventis)
- Parkinson's Disease
- E2007 (Eisai)
- Istradefylline (Kyowa Hakko)
- Safinamide (Newron)
- SLV308 (Solvay)
- Spheramine (Schering AG/Titan)
- GLOBAL SALES FORECASTS OF PHASE III AD and PD DRUGS 2006 - 2012
- Sales Forecasts of Phase III Developmental AD and PD Drugs
- Model assumptions
- ANALYSIS OF PHASE II DRUGS
- New Drugs in Early Clinical Development to Treat AD and PD
- AD Agents
- PD Agents
- AD agents
- Bapineuzumab (Wyeth/Elan)
- Other promising Phase II drugs
- CX717 (Cortex Pharmaceuticals)
- EVT 101 (Evotec)
- Ketasyn (Accera)
- MEM 1003 (Memory Pharmaceuticals)
- PBT2 (Prana)
- SGS-742 (Saegis Pharmaceuticals)
- PD drugs
- SR 57667 (sanofi-aventis)
- Talampanel (IVAX)
- VR040 (Vectura)
- COMPETITOR RATIO ANALYSIS PRODUCTS/DRUGS
- CR Analysis of AD Agents Approved by 2012 - Based on Drug Class
- CR Analysis of PD Agents Approved by 2012 - Based on Drug Class
- COMPETITOR RATIO ANALYSIS - COMPANIES
- CR Analysis of AD and PD Agents Approved by 2012 - Based on Company
- WINNERS & LOSERS
- Summary of Key Companies and Drugs in the AD and PD Market by 2012
- DISCONTINUATION OF DRUGS
- AD and PD drugs discontinued from clinical development
- NEURODEGENERATIVE APPENDIX 1
- Phase transition probability
- NEURODEGENERATIVE APPENDIX 2
- AD Patient Model
- Summary of AD Patient Population Forecasts
- NEURODEGENERATIVE APPENDIX 3
- PD Patient Model
- Summary of PD Patient Population Forecasts
- NEURODEGENERATIVE APPENDIX 4
- Global AD Drugs Sales 2005-2012
- Global AD Drug Sales 2005A-2012E
- NEURODEGENERATIVE APPENDIX 5
- Global PD Drugs Sales 2005-2012
- Global PD Drug Sales 2005A-2012E
- NEURODEGENERATIVE APPENDIX 6
- Competitor Ratio Analysis Criteria
- Key AD & PD Drugs on the Market by 2012
- NEURODEGENERATIVE GLOSSARY
- NEURODEGENERATIVE REFERENCES
- ACRONYMS
|
